Positive results from Nile's cenderitide Phase 1 trial on chronic heart failure News-Medical.net Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced results from its recently completed Phase 1 clinical trial evaluating the pharmacokinetics (PK), ... Nile Phase I trial of cenderitide meets primary end-point |
